OncoSTING is developing novel bladder cancer therapies by harnessing the potency of standard BCG immunotherapy and long-lived delivery of potent STING agonists using BCG as the delivery vehicle.
Member count: 1-10
Investors 1
| Date | Name | Website |
| - | Johns Hopk... | ventures.j... |